Okay.
Mitsubishi Chemical Group's consolidated financial results for the fiscal year ending March 31, 2022, note the following:
...MCG has determined that it will not pursue the commercialization of the VLP vaccine. In addition, MCG judged that it was not viable to continue to make further investment in the commercialization of Medicago's development products, and decided to cease all of its operations at Medicago and proceed with an orderly wind up of its business and operations. Consequently, since the investment [has become] unrecoverable, the carrying amount of Medicago's vaccine manufacturing equipment and goodwill related to its business and operations was reduced to the recoverable amount....
Can you outline why MCG came to the determination that it was not viable to continue to make further investments in the commercialization of Medicago's development products?